Market Research Report
Bioreactor Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
|Bioreactor Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027|
Published: June 13, 2022
IMARC Services Private Limited
Content info: 145 Pages
Delivery time: 2-3 business days
The global bioreactor market reached a value of US$ 5.64 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 11.84 Billion by 2027, exhibiting a CAGR of 12.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
A bioreactor refers to a fermentation vessel, wherein biological reactions are executed for developing enzymes and various organisms, including bacteria, animal cells and yeast, under controlled conditions. It aids in producing several pharmaceuticals, such as vaccines and monoclonal antibodies, maintaining the inhomogeneous state of the cells to obtain the desired output, and monitoring the environmental conditions for promoting the cell formation process. On account of these properties, a bioreactor is extensively used by biopharmaceutical companies, research and development (R&D) institutions, and contract research organizations (CROs). At present, it is commercially available in glass, stainless steel, and single-use material types.
The global bioreactor market is majorly driven by the increasing prevalence of various chronic diseases, such as cancer and diabetes, especially amongst the steadily rising geriatric population. In line with this, the growing need for preventive vaccines, particularly during the sudden outbreak of the coronavirus disease (COVID-19) pandemic, have prompted several pharmaceutical companies to considerably invest in research and development (R&D) activities to extend their production capacities. This, in turn, is inflating the overall sales of bioreactors across the globe. Additionally, significant technological advancements, such as the introduction of single-use bioreactors (SUBs) for optimizing the quality, flexibility, and scalability of microorganisms' formation operations with minimal cost and energy requirements, are positively stimulating the market growth. Apart from this, increasing biopharmaceuticals manufacturing capacities across developing nations, along with the rising demand for bioreactors that support modern, evolving, high-cell density, and intensified clinical processes requiring high oxygen transfer and great carbon dioxide (CO2) removal are propelling the market growth. Other factors, such as rapid expansion in the pharmaceutical and biologics sectors, the escalating need for effective treatment drugs, and the increasing awareness among consumers regarding the formulation and availability of personalized medicines, are contributing to the market growth significantly.
IMARC Group provides an analysis of the key trends in each sub-segment of the global bioreactor market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, usage, scale and control type.
The competitive landscape of the industry has also been examined along with the profiles of the key players being 2mag AG, bbi-biotech GmbH, Bioengineering AG, Eppendorf SE, Getinge AB, Infors AG, Merck KGaA, Pall Corporation (Danaher Corporation), Sartorius AG, Solaris Biotechnology Srl and Thermo Fisher Scientific Inc.